AIMS: Anthracycline-induced cardiotoxicity (AIC) is a serious adverse effect among cancer patients. A central mechanism of AIC is irreversible mitochondrial damage. Despite major efforts, there are currently no effective therapies able to prevent AIC. METHODS AND RESULTS: Forty Large-White pigs were included. In Study 1, 20 pigs were randomized 1:1 to remote ischaemic preconditioning (RIPC, 3 cycles of 5 min leg ischaemia followed by 5 min reperfusion) or no pretreatment. RIPC was performed immediately before each intracoronary doxorubicin injections (0.45 mg/kg) given at Weeks 0, 2, 4, 6, and 8. A group of 10 pigs with no exposure to doxorubicin served as healthy controls. Pigs underwent serial cardiac magnetic resonance (CMR) exams at baseline and at Weeks 6, 8, 12, and 16, being sacrifice after that. In Study 2, 10 new pigs received 3 doxorubicin injections (with/out preceding RIPC) and were sacrificed at week 6. In Study 1, left ventricular ejection fraction (LVEF) depression was blunted animals receiving RIPC before doxorubicin (RIPC-Doxo), which had a significantly higher LVEF at Week 16 than doxorubicin treated pigs that received no pretreatment (Untreated-Doxo) (41.5 ± 9.1% vs. 32.5 ± 8.7%, P = 0.04). It was mainly due to conserved regional contractile function. In Study 2, transmission electron microscopy (TEM) at Week 6 showed fragmented mitochondria with severe morphological abnormalities in Untreated-Doxo pigs, together with upregulation of fission and autophagy proteins. At the end of the 16-week Study 1 protocol, TEM revealed overt mitochondrial fragmentation with structural fragmentation in Untreated-Doxo pigs, whereas interstitial fibrosis was less severe in RIPC+Doxo pigs. CONCLUSION: In a translatable large-animal model of AIC, RIPC applied immediately before each doxorubicin injection resulted in preserved cardiac contractility with significantly higher long-term LVEF and less cardiac fibrosis. RIPC prevented mitochondrial fragmentation and dysregulated autophagy from AIC early stages. RIPC is a promising intervention for testing in clinical trials in AIC.
AIMS: Anthracycline-induced cardiotoxicity (AIC) is a serious adverse effect among cancer patients. A central mechanism of AIC is irreversible mitochondrial damage. Despite major efforts, there are currently no effective therapies able to prevent AIC. METHODS AND RESULTS: Forty Large-White pigs were included. In Study 1, 20 pigs were randomized 1:1 to remote ischaemic preconditioning (RIPC, 3 cycles of 5 min leg ischaemia followed by 5 min reperfusion) or no pretreatment. RIPC was performed immediately before each intracoronary doxorubicin injections (0.45 mg/kg) given at Weeks 0, 2, 4, 6, and 8. A group of 10 pigs with no exposure to doxorubicin served as healthy controls. Pigs underwent serial cardiac magnetic resonance (CMR) exams at baseline and at Weeks 6, 8, 12, and 16, being sacrifice after that. In Study 2, 10 new pigs received 3 doxorubicin injections (with/out preceding RIPC) and were sacrificed at week 6. In Study 1, left ventricular ejection fraction (LVEF) depression was blunted animals receiving RIPC before doxorubicin (RIPC-Doxo), which had a significantly higher LVEF at Week 16 than doxorubicin treated pigs that received no pretreatment (Untreated-Doxo) (41.5 ± 9.1% vs. 32.5 ± 8.7%, P = 0.04). It was mainly due to conserved regional contractile function. In Study 2, transmission electron microscopy (TEM) at Week 6 showed fragmented mitochondria with severe morphological abnormalities in Untreated-Doxo pigs, together with upregulation of fission and autophagy proteins. At the end of the 16-week Study 1 protocol, TEM revealed overt mitochondrial fragmentation with structural fragmentation in Untreated-Doxo pigs, whereas interstitial fibrosis was less severe in RIPC+Doxo pigs. CONCLUSION: In a translatable large-animal model of AIC, RIPC applied immediately before each doxorubicin injection resulted in preserved cardiac contractility with significantly higher long-term LVEF and less cardiac fibrosis. RIPC prevented mitochondrial fragmentation and dysregulated autophagy from AIC early stages. RIPC is a promising intervention for testing in clinical trials in AIC.
Authors: Hui-Ming Chang; Tochukwu M Okwuosa; Tiziano Scarabelli; Rohit Moudgil; Edward T H Yeh Journal: J Am Coll Cardiol Date: 2017-11-14 Impact factor: 24.094
Authors: Teresa López-Fernández; Ana Martín García; Ana Santaballa Beltrán; Ángel Montero Luis; Ramón García Sanz; Pilar Mazón Ramos; Sonia Velasco Del Castillo; Esteban López de Sá Areses; Manuel Barreiro-Pérez; Rocío Hinojar Baydes; Leopoldo Pérez de Isla; Silvia Cayetana Valbuena López; Regina Dalmau González-Gallarza; Francisco Calvo-Iglesias; Juan José González Ferrer; Antonio Castro Fernández; Eva González-Caballero; Cristina Mitroi; Meritxell Arenas; Juan Antonio Virizuela Echaburu; Pascual Marco Vera; Andrés Íñiguez Romo; José Luis Zamorano; Juan Carlos Plana Gómez; José Luis López Sendón Henchel Journal: Rev Esp Cardiol (Engl Ed) Date: 2017-03-18
Authors: Andreas Goetzenich; Nima Hatam; Alma Zernecke; Christian Weber; Tanja Czarnotta; Rüdiger Autschbach; Stefan Christiansen Journal: J Heart Lung Transplant Date: 2009-10 Impact factor: 10.247
Authors: Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh Journal: Nat Med Date: 2012-10-28 Impact factor: 53.440
Authors: Zachary M Gertz; Chad Cain; Donatas Kraskauskas; Teja Devarakonda; Adolfo G Mauro; Jeremy Thompson; Arun Samidurai; Qun Chen; Sarah W Gordon; Edward J Lesnefsky; Anindita Das; Fadi N Salloum Journal: JACC CardioOncol Date: 2019-12-17
Authors: R M Bell; M Basalay; H E Bøtker; S Beikoghli Kalkhoran; R D Carr; J Cunningham; S M Davidson; T J England; S Giesz; A K Ghosh; P Golforoush; A V Gourine; D J Hausenloy; G Heusch; B Ibanez; P Kleinbongard; S Lecour; K Lukhna; M Ntsekhe; M Ovize; A D Salama; G Vilahur; J M Walker; D M Yellon Journal: Basic Res Cardiol Date: 2022-08-15 Impact factor: 12.416
Authors: Marco Bruno Morelli; Chiara Bongiovanni; Silvia Da Pra; Carmen Miano; Francesca Sacchi; Mattia Lauriola; Gabriele D'Uva Journal: Front Cardiovasc Med Date: 2022-04-15
Authors: Jan M Leerink; Mabel van de Ruit; Elizabeth A M Feijen; Leontien C M Kremer; Annelies M C Mavinkurve-Groothuis; Yigal M Pinto; Esther E Creemers; Wouter E M Kok Journal: J Mol Med (Berl) Date: 2021-05-29 Impact factor: 4.599